CBD vs THC: can cannabidiol take the edge off cannabis's psychoactive effects?
NCT ID NCT06099379
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether different doses of cannabidiol (CBD) can reduce the psychoactive effects of THC in healthy adults who use cannabis occasionally. One hundred participants will inhale various combinations of CBD and THC and report their experiences. The goal is to find out if CBD can make the 'high' from THC less intense or more manageable.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cannabidiol (CBD) and tetrahydrocannabinol (THC) - inhaled
- What this could lead to
- If it works, this could help people better understand how CBD might reduce the 'high' from THC, potentially leading to safer cannabis products.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. The results may not apply to regular users or medical conditions, and the effects of CBD on THC are still uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 49 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Between 21 and 49 years of age, inclusively; 2. Have used cannabis at least once in their lifetime and have used cannabis three days or less in the 30 days prior to enrollment; 3. Be able to provide a signed informed consent; 4. Willing to comply with study procedures and requirements as per protocol; 5. Have a forced expiratory volume in first second (FEV) less than or equal to 90 %; 6. Able to communicate and understand English or French language; 7. For female participants: a. No childbearing potential, defined as: i. postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or ii. Documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or b. For female of childbearing potential: i. Must have negative pregnancy test result at screening and at subsequent visits. ii. AND have no pregnancy plan while on the study iii. AND must agree to use a medically accepted method of birth control throughout the study. Exclusion criteria Participants will be excluded if any of the following criteria are met: 1. Any disabling medical condition, as assessed by medical history, physical exam, vital signs and/or laboratory assessments that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent; 2. Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or current suicidality based on the Mini International Neuropsychiatric Interview); 3. Any other disabling, unstable or acute mental condition that, in the opinion of the study physician, precludes safe participation in the study or ability to provide fully informed consent; 4. Known chronic liver disease or aspartate transaminase/alanine transaminase (AST/ALT) two times higher than upper limit of normal values at screening visit; 5. Blood pressure higher than 130/80 mmHg; 6. Kidney disorders; 7. Bleeding disorders; 8. Current moderate or severe DSM-5 substance use disorder (except nicotine) according to SCID-V; 9. Currently pregnant, breastfeeding or planning to become pregnant either at screening or while enrolled in the study; 10. Pending legal action or other reason that, in the opinion of the study physician, might prevent study completion; 11. Use of medication within 7 days of experimental sessions; which, in the opinion of the Investigator, may interact with cannabis. 12. Participation in clinical studies or undergoing other investigational procedure involving cannabis or cannabinoids administration within 30 days prior to randomization. 13. Resting heart rate over 100 beats per minute. 14. Current body mass index (BMI) over 29.9 kg/m2. 15. Any clinically significant electrocardiogram abnormalities at screening visit.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre de recherche du Centre Hospitalier Universitaire de Montréal
RECRUITINGMontreal, Quebec, H2X0A9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which cannabis warnings stick? study puts messages to the test
- Cannabis compounds may rewire memory retrieval, brain scans suggest
- Hemp seed allergy risk under the microscope: new study launches
- Study tests if potent weed vapes lead to overconsumption
- Hemp lotion absorption under the microscope: new study launches
- Citrus compound meets cannabis: scientists study their combined effects